Suppressing the immune system to reduce brain inflammation, a known contributor to Parkinson’s disease progression, may offer a promising new strategy for slowing the disease, early trial results suggest. Specifically, azathioprine, a commonly used drug that suppresses immune activity, reduced motor symptoms and improved cognitive function in people…

The investigational liquid therapy ND0612 — an around-the-clock supply of levodopa/carbidopa infused via a pump under the skin — provides more stable motor control in people with Parkinson’s disease who experience motor fluctuations than standard immediate-release levodopa/carbidopa. That’s according to data from the randomized portion of the…

Crexont, an extended-release oral formulation of carbidopa and levodopa,  significantly improved sleep quality in people with Parkinson’s disease. That’s according to data based on additional analysis of the Phase 3 RISE-PD trial (NCT03670953). The results were detailed in a presentation, “Conversion to CREXONT in…

ION859, an injectable treatment being developed by Ionis Pharmaceuticals, was generally safe and well tolerated, and it reduced the levels of LRRK2 — a protein often overactive in Parkinson’s disease — even in patients without mutations in the gene that encodes it. These are data from a now-completed…

My family was feeling very helpless and alone after my husband, Arman, was diagnosed with early-onset Parkinson’s disease in 2009. He was only 38 years old then, and we were left floundering for a sense of hope. Soon after his diagnosis, close friends and family members approached me…